Navigation Links
Biovista and the CFIDS Association of America Achieve Drug Repositioning Milestone with Pre-IND Meeting
Date:5/29/2013

CHARLOTTESVILLE, Virginia and CHARLOTTE, North Carolina, May 29, 2013 /PRNewswire/ --

Biovista and the CFIDS Association of America announced today the successful completion of the first phase of their collaboration. Funded as part of the CFIDS' Research Institute Without Walls, Biovista identified candidate treatments for CFS using its state-of-the-art COSS approach. Two candidate treatments, including a combination therapy, were identified and are being prepared for proof-of-concept clinical trials, with an FDA pre-IND meeting scheduled in Q3 2013.

"We are very excited to have reached this stage within a year of starting our collaboration. We look forward to furthering our understanding of this complex disease and developing a treatment that will improve CFS patients' quality of life," said Dr. Andreas Persidis , Biovista's CEO. "Our work is an example of things to come in terms of novel collaboration models that promise to accelerate treatment development and, through the drug repositioning approach, do so cost effectively," Dr Persidis added.

"There is a big gap in the pipeline that moves basic laboratory research into safe and effective treatments. Without a bridge to bring discoveries to the clinic, laboratory research rarely becomes more than a paper. We are providing the means for basic researchers to move discoveries through the translational research pipeline with our Research Institute Without Walls," said Kim McCleary , president and CEO of CFIDS.

"Therapies for ME/CFS are an unmet medical need. This is largely due to the lack of translating the scientific knowledge into meaningful impact for patients," added Dr. Suzanne D. Vernon , Scientific Director of CFIDS. "We understand the ME/CFS knowledgebase and know how to fill this gap. Biovista recognized the opportunity for discovery. This drug repositioning project is an excellent example of effective use of existing information to make a new treatment discovery."

About Biovista

Biovista finds novel uses for existing drugs and profiles their side effects using mechanism of action analysis. Biovista develops its own pipeline in CNS, oncology, auto-immune and rare diseases and collaborates with biopharmaceutical companies and Patient Groups on indication expansion, portfolio de-risking, and adverse event prediction. (http://www.biovista.com).

About CFIDS

The CFIDS Association of America is at the leading edge of ME/CFS research. For more information, please visit The Association's web site at http://www.cfids.org or their research blog at http://www.Research1st.org

Contacts
Biovista
Dr. Andreas Persidis
andreasp@biovista.com
T: +1-434-242-6514
 
The CFIDS Association of America
Dr. Suzanne D. Vernon
sdvernon@cfids.org


'/>"/>
SOURCE Biovista
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
3. Washington State Medical Association (WSMA) Urges Adults to Get Recommended Immunizations
4. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
5. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
6. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
9. Attack on the Website of the American Pharmacists Association
10. China Botanic Sponsors Wild Plant Protection Association of China Meeting; Expects to Lead the Siberian Ginseng Conservation Association
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016 Kalorama Information ... (Electronic Medical Records) market in a recent white paper.  ... switches, Increased physician usage, a growing market are among ... noted in Kalorama,s report EMR 2016: The ... marks Kalorama,s seventh complete study of the EMR industry, ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
(Date:4/29/2016)... New Jersey , April 29, 2016 /PRNewswire/ ... Software Suite for Life Sciences, Product Development Capabilities ... Global Life Science Customer Base . ... solutions provider, today announced the acquisition of Skura ... a global leader in adaptive sales enablement technology ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the ... pet anxiety. "Pet owners often think anxiety only manifests itself as trembling or ... other ways, and there’s things that be done about it,” says Dr. Jim Lowe, ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... it has been selected by Tidelands Health, a three hospital system in South ... be constantly on the lookout for technology that enhances communication, drives workflow efficiencies ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced ... medical situations or practice tricky or rare procedures in an environment that looks and ... Center is also available to inventors and “hackers” to develop and test new devices ...
(Date:5/3/2016)... ... ... Each year, about 800,000 people suffer from cerebral vascular accidents, or strokes. ... for one death every four minutes. Many people who survive a stroke are ... a video series called “Your Brain,” in conjunction with its medical journal “Balance,” in ...
(Date:5/3/2016)... ... 2016 , ... Ogawa World USA introduced the first of its kind ... Smart Application. The Smart 3D combines the best in technological advancement, design, and massage ... and specialized massage program, each user has a tailored experience unparalleled by any other ...
Breaking Medicine News(10 mins):